Neurosense TherapeuticsNRSN
13F holders, Q2 2026 (June 30)12holders −1
2new positions
3sold out
$0.72avg. 13F price*
At the end of Q2 2026, 12 institutions reported holding Neurosense Therapeutics Ltd. (NRSN) in their 13F filings, down 1 from Q1 2026. 2 opened new positions and 3 sold out. The largest holders were UBS Group AG ($78K), Independent Advisor Alliance ($72K) and Yorkville Advisors Global, LP ($56K).
- Company
- Neurosense Therapeutics Ltd.
- CUSIP
- M74240108
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $15K |
| Exits | 3 | $85K |
All 13F filers, Q1 2026 → Q2 2026: 131,528 shares bought and 113,626 shares sold, net +17,902 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 12 holders
| UBS Group AG | 0.00% | Add +121.3% | 108,636 | $78K |
| Independent Advisor Alliance | 0.00% | Add +100.0% | 100,000 | $72K |
| Yorkville Advisors Global, LP | 0.07% | No change | 78,000 | $56K |
| Commonwealth Equity Services, LLC | 0.00% | No change | 22,775 | $16K |
| PNC Financial Services Group, Inc. | 0.00% | No change | 21,150 | $15K |
| Pathstone Holdings, LLC | 0.00% | No change | 16,528 | $12K |
| Geode Capital Management, LLC | 0.00% | No change | 15,870 | $11K |
| XTX Topco Ltd | 0.00% | New | 11,473 | $8K |
| Creative Planning | 0.00% | Reduce -4.2% | 11,410 | $8K |
| HRT Financial LP | 0.00% | New | 10,515 | $7K |
| Jones Financial Companies LLLP | 0.00% | No change | 1,000 | $757 |
| SBI Securities Co., Ltd. | 0.00% | Reduce -3.8% | 255 | $184 |
"% of holder's portfolio" is NRSN's weight in each manager's 13F, not the share of Neurosense Therapeutics Ltd. the manager owns.